Pernix Therapeutics Holdings Q3 Loss Widens; Cuts FY13 Revenue Range

(RTTNews) - Pernix Therapeutics Holdings, Inc. (PTX) reported a third-quarter net loss of $6.0 million or $0.16 per share, wider than $0.3 million or $0.01 per share in the comparable quarter last year.

On average, 5 analysts polled by Thomson Reuters expected the company to earn $0.09 per share for the quarter. Analysts' estimates typically exclude special items.

Net revenues for the latest quarter rose 1% to $18.30 million from $18.13 million last year, while five analysts expected revenues of $23.06 million for the quarter.

Looking ahead to the fourth quarter, the company expects net revenue to be approximately $22.0 million. Analysts currently expect revenue of $27.76 million for the fourth quarter.

The Company lowered its net revenue guidance for the full year 2013 to $80.0 million, from the previous range of $90.0 to $100.0 million. Analysts now expect full year 2013 revenue of $93.69 million.